Table 1.
Demographic and baseline characteristics of participants.
| Phase I trials | Phase II trials | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Europe | East Africa | Europe | East Africa | West Africa | West Africa | |||
| UK | Kenya | Tanz./Ug. | UK/France | Ken./Tanz. | BFA/IVC | Sierra Leone | ||
| EBL1001 | EBL1003 | EBL1004 | EBL2001 | EBL2002 | EBL3001 | |||
| Part., no. | 14 | 15 | 15 | 71 | 79 | 58 | 235 | 487 |
| Sex | ||||||||
| Men | 4 (29%) | 11 (73%) | 10 (67%) | 32 (45%) | 45 (57%) | 44 (75%) | 203 (86%) | 349 (72%) |
| Women | 10 (71%) | 4 (27%) | 5 (33%) | 39 (55%) | 34 (43%) | 14 (24%) | 32 (14%) | 138 (28%) |
| Age (yrs) | 37.6 (9.3) | 23.7 (2.8) | 26.5 (6.8) | 41.2 (14.7) | 34.1 (13.5) | 34.1 (10.8) | 27.2 (10.0) | 31.3 (12.4) |
| BMI (kg/m2) | 26.1 (3.3) | 22.5 (4.1) | 22.9 (4.2) | 25.4 (4.5) | 23.8 (4.0) | 23.0 (3.4) | 21.9 (3.3) | 23.0 (3.9) |
| Weight (kg) | 73.7 (13.7) | 63.3 (12.7) | 63.5 (11.7) | 74.7 (14.7) | 63.9 (10.2) | 67.2 (9.9) | 62.4 (9.4) | 65.4 (11.7) |
Data are n (%) or mean (SD). Only healthy adults receiving Ad26.ZEBOV followed by MVA-BN-Filo 56 days later were selected within each of the 6 trials.
Part. participants, no. number, yrs years, kg kilograms, m meter, UK United Kingdom, Tanz. Tanzania, Ug. Uganda, BFA Burkina Faso, IVC Ivory Coast.